16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest a hydrogel-based formulation of the GCCR agonist triamcinolone acetonide could help treat RA and other forms of inflammatory arthritis. The hydrogel contains injectable triglycerol monostearate that...
19:10 , Aug 22, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles that promote tumor platelet phagocytosis could be used to delivery cancer therapies. The nanoparticles consist of a polyethylenimine (PEI)-poly(glycolic acid) core that contains drug cargo and a mAb targeting glycoprotein Ib (platelet) α...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

AQU-005: Phase I started

NeuroMax began an open-label, Russian Phase I trial to evaluate AQU-005 in 24 healthy volunteers. NeuroMax plans to begin proof-of-concept (POC) trials of the product in patients with neuropathic pain in 4Q16. NeuroMax has worldwide...
07:00 , Sep 24, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 2 (MMP2); MMP9; MMP14

Cancer INDICATION: Cancer Cell and mouse studies identified an inhibitor of MMP2, MMP9, and MMP14 that could help treat cancer. Chemical synthesis and testing in an MMP binding assay of sulfonamide hydroxamate analogs identified a compound that...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Matrix metalloproteinase 2 (MMP2)-activated, chemotherapeutic nanocarriers for targeted drug delivery MMP2-activated nanocarriers could provide...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Secondary Cherenkov-induced fluorescence imaging (SCIFI) to detect markers of disease activity Mouse studies suggest SCIFI could help detect and monitor...
07:00 , Jul 15, 2013 |  BioCentury  |  Regulation

Coding for utility

New, tougher requirements for obtaining Medicare coverage are increasing the cost and time needed to get laboratory-developed molecular diagnostics onto the market and decreasing the certainty that they will be covered. Empowered by a new CMS...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Predictive Biosciences diagnostic news

Predictive Biosciences is ceasing operations and laying off all 91 employees after CMS contractor CGS Administrators LLC decided to deny coverage for the company's bladder cancer diagnostics. CEO Pierre Cassigneul told BioCentury that the company...
07:00 , Sep 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Matrix metalloproteinase 2 (MMP2); MMP9 In vitro and mouse studies identified the endohedral metallofullerenol Gd@C82(OH)22...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program (see "Repurposing pharma compounds"). The compounds provided...